Affiliation:
1. Clinique des Maladies Infectieuses et Laboratoire de Microbiologie, Institut Jules Bordet, Bruxelles, Belgium.
Abstract
Ten volunteers received piperacillin (4 g), piperacillin (4 g) plus tazobactam (0.5 g) (Tazocin), and ticarcillin (3 g) plus clavulanic acid (0.2 g) (Timentin) intravenously over 30 min in a cross-over blinded scheme. Blood samples were obtained 0.5 and 3 h after the end of infusion to measure by (high-pressure liquid chromatography) the concentration and bactericidal titers against 70 gram-negative bacilli. Serum time-kill curves were done against 35 strains to measure killing rates and area under the time-kill curve. Using the measure of serum bactericidal activity, ticarcillin-clavulanic acid and piperacillin-tazobactam were equally effective against Pseudomonas aeruginosa, Escherichia coli, Enterobacter cloacae, Serratia marcescens, and Bacteroides fragilis. Piperacillin-tazobactam was superior to ticarcillin-clavulanic acid against piperacillin-resistant Klebsiella pneumoniae (4 to 16 times) and S. marcescens (2 to 4 times). By using the area under the time-kill curve, piperacillin-tazobactam was equivalent to ticarcillin-clavulanic acid against piperacillin-susceptible strains; piperacillin-tazobactam was significantly more active than piperacillin against piperacillin-resistant strains and was more active than ticarcillin-clavulanic acid when the sample obtained 3 h after the end of infusion to volunteers was considered. Serum piperacillin concentrations (mean +/- standard error of the mean; in mg/liter) were 115 +/- 13 at 0.5 h and 7.4 +/- 1.4 at 3 h after the administration of piperacillin alone and 105.5 +/- 12.6 (0.5 h) and 7.7 +/- 1.6 after the administration of piperacillin-tazobactam. Serum tazobactam concentrations (in milligram per liter) were 13.1 +/- 1.4 at 0.5 h and 1.2 +/- 0.2 at 3 h. The piperacillin-tazobactam ratio was 8 +/- 0.3 at 0.5 h and 6.2 +/- 0.5 at 3 h. Piperacillin-tazobactam appears promising against beta-lactamase-producing gram-negative bacilli.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference25 articles.
1. Interactions of tazobactam and clavulanate with inducibly- and constitutivelyexpressed class I ,-lactamases;Akova M.;J. Antimicrob. Chemother.,1990
2. Comparative activity of P-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with P-lactams against P-lactamase-producing anaerobes;Appelbaum P. C.;Antimicrob. Agents Chemother.,1986
3. Comparative activities of the P-lactamase inhibitors YTR830, sodium clavulanate, and sulbactam combined with amoxicillin or ampicillin;Aronoff S. C.;Antimicrob. Agents Chemother.,1984
4. Comparative efficacy of amoxycillin-clavulanate, cloxacillin, and vancomycin against methicillin-sensitive and methicillinresistant Staphylococcus aureus endocarditis in rats;Cantoni L.;J. Infect. Dis.,1989
5. Value of serum tests in combined therapy of endocarditis;Drake T. A.;Antimicrob. Agents Chemother.,1983
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献